Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2014

View Archived Issues

In vivo data for the novel anti-Abeta-oligomer antibody ACU-3B3

Phase II results presented for clazakizumab in patients with active psoriatic arthritis

Endo acquires rights to Natesto testosterone nasal gel

OncoSec Medical confirms phase II trial of ImmunoPulse in head and neck cancer

Zymeworks and Merck & Co. expand bispecific antibody collaboration

MIPS, Monash University and Takeda form strategic research alliance in gastroenterology

Calithera licenses Mars Symbioscience's arginase inhibitors

La Jolla Pharmaceutical and George Washington University sign license agreement relating to LJPC-501

Ono Pharmaceutical presents a novel dual Axl/Mer inhibitor, ONO-9330547

Spark Therapeutics and Pfizer establish gene therapy collaboration in hemophilia B

Bayer and DNDi sign agreement to develop oral drug for river blindness

Alize Pharma reports phase I findings on AZP-531

Myelo-001 for the prevention of chemotherapy-induced myelosuppression

Spanish researchers report development of neuroprotective steroidal nitrones

Roche researchers prepare and test CYP11B2 inhibitors

Chinese institute patents new antiviral compounds

Reslizumab improves quality of life of asthma patients with elevated eosinophils

Luoda Biosciences synthesizes novel kinase inhibitors

FDA approves nine-valent HPV vaccine Gardasil 9

Immunovaccine receives FDA fast track designation for DPX-Survivac

Eculizumab receives orphan drug designation in Japan for myasthenia gravis

FDA grants orphan drug designation to rNAPc2 for Ebola

Preclinical studies show promising results on APG-1252 as a novel Bcl-2/Bcl-xL inhibitor

Ono, BMS and Kyowa Hakko Kirin to conduct combination study of Opdivo

U.K. researchers gain access to 68 deprioritized compounds under MRC program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...